AI Summary Hepatocellular carcinoma accounts for 75% to 86% of primary liver cancers, and cirrhosis from any cause is present in more than 80% of people who develop it.
Medically reviewed
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer — cancer that starts in the liver's main cells, called hepatocytes. It is diagnosed more often in men and typically appears after age 50, most often in people who already have a chronic liver disease such as cirrhosis, chronic hepatitis B, or chronic hepatitis C.
HCC usually develops over years or decades in someone with underlying liver damage; cirrhosis is present in more than 80% of people who develop it. Early-stage HCC, when it is still confined to the liver, can often be treated successfully with surgery or transplant, which is why regular monitoring matters for people with cirrhosis or chronic viral hepatitis.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
About HCC
Hepatocellular carcinoma (HCC) is cancer that starts in the liver's main cells, called hepatocytes. It is the most common type of primary liver cancer — cancer that begins in the liver itself, rather than spreading there from another organ. HCC is diagnosed more often in men than women and is most often diagnosed in people age 50 or older.
HCC usually develops over years or even decades in someone who already has chronic liver disease. Cirrhosis, from any underlying cause, is the strongest risk factor and is present in more than 80% of people who develop HCC, and chronic hepatitis B or C infection also raises risk significantly.
Liver cancer is not one disease. Along with HCC, the other common type of primary liver cancer is cholangiocarcinoma, which starts in the bile ducts. Cancer that spreads to the liver from another organ, such as the colon or breast, is called metastatic liver cancer and is actually more common than cancer that starts in the liver itself.
Once HCC is identified, it can grow quickly, so how far it has spread at diagnosis makes a major difference in outlook and treatment options.
How HCC May Feel
Early hepatocellular carcinoma often causes no symptoms at all — signs and symptoms are highly variable and may not appear until later stages. When symptoms do show up, they are usually related to the tumor itself or to underlying liver disease.
Getting Checked
Doctors diagnose hepatocellular carcinoma through a combination of physical examination, blood tests, imaging, and sometimes biopsy. In people already known to have cirrhosis or chronic hepatitis B, imaging alone may be enough to confirm the diagnosis; in others, a biopsy may be needed.
In people with cirrhosis or chronic hepatitis B, characteristic imaging findings on CT or MRI can confirm HCC without a biopsy. In everyone else, biopsy is generally needed to confirm the diagnosis.
Care & Treatment
Treatment for hepatocellular carcinoma depends on the tumor's size, number, and location; how well the rest of the liver is functioning; whether cirrhosis is present; and the person's overall health. Because of this, treatment plans are highly individualized and usually involve a multidisciplinary care team.
For early-stage HCC, surgical resection (removing the part of the liver with the tumor) is the treatment of choice when there is no underlying cirrhosis. In people with cirrhosis or those who meet transplant criteria, a liver transplant can be curative because it treats both the cancer and the underlying liver disease.
When surgery is not an option, doctors may use image-guided, localized treatments delivered directly to the tumor. These include tumor ablation (radiofrequency, microwave, or ethanol injection), transarterial chemoembolization (TACE), which delivers chemotherapy directly into the tumor's blood supply while blocking blood flow, and transarterial radioembolization (TARE), which delivers radiation the same way.
For advanced HCC that has spread beyond the liver or cannot be treated locally, systemic therapy is used. Immunotherapy combinations, such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab, are the preferred first-line options for people with preserved liver function. Targeted therapies that block proteins involved in tumor growth are another systemic option.
There is no single treatment for HCC that fits everyone. Treatment choice depends heavily on tumor stage and how well the liver is functioning, which is why specialist evaluation and sometimes a second opinion are important.
How HCC Develops
Hepatocellular carcinoma almost always develops on top of existing liver damage. Chronic liver disease slowly injures liver cells over years, and that ongoing injury and scarring create the conditions in which cancer can form.
Cirrhosis and chronic hepatitis B or C infection are the strongest drivers of HCC risk. Vaccination against hepatitis B, treating hepatitis C, limiting alcohol, and managing weight and diabetes all help lower risk.
When to Get Checked
Because early HCC often causes no symptoms, most cases are found through planned surveillance rather than because someone feels unwell. Knowing when to get checked, and who should be screened regularly, can make an important difference in outcomes.
Surveillance with ultrasound, often combined with an AFP blood test, is recommended every 6 months for people with cirrhosis of any cause, and for people with chronic hepatitis B infection who meet certain age criteria even without cirrhosis.
You should speak with a healthcare provider if you have cirrhosis, chronic hepatitis B or C, hereditary hemochromatosis, or a family history of liver cancer, even if you feel well. You should also seek prompt evaluation if you notice new abdominal pain, unexplained weight loss, jaundice, or abdominal swelling.
Early-stage HCC, confined to the liver, can often be treated successfully with surgery or transplant. Because outcomes worsen substantially once the cancer spreads, catching it early through regular surveillance gives the most treatment options and the best outlook.
A hepatologist or gastroenterologist experienced in liver cancer can coordinate surveillance, interpret imaging, and guide treatment decisions alongside oncology and surgical specialists.
Eating & Liver Health
Diet cannot treat hepatocellular carcinoma on its own, but good nutrition supports liver function during and after cancer treatment and helps manage the underlying liver disease, such as cirrhosis or fatty liver disease, that often comes with it.
A liver-friendly eating pattern generally emphasizes whole foods, vegetables, fruits, lean proteins, and healthy fats while limiting added sugars, alcohol, and highly processed foods. During active cancer treatment such as TACE, patients are also advised to stay well hydrated and follow their care team's specific nutrition guidance.
Nutritional needs vary widely depending on the stage of liver disease, treatment plan, and overall health, so it's important to work with your care team on an eating plan that fits your situation.
Explore Liver DietCommon Questions
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, meaning it starts in the liver's own cells (hepatocytes) rather than spreading there from another organ. It usually develops over years or decades in people who already have chronic liver disease, most often cirrhosis or chronic hepatitis B or C. It is diagnosed more often in men and most often after age 50. HCC is different from cholangiocarcinoma, which starts in the bile ducts, and from metastatic liver cancer, which spreads to the liver from another organ. Early HCC often causes no symptoms, which is why regular monitoring matters for people at risk.
Long-term liver damage is the main cause. Cirrhosis of any cause is the strongest risk factor and is present in more than 80% of people who develop HCC. Chronic hepatitis B or C infection, long-term heavy alcohol use, and fatty liver disease that has progressed to inflammation and scarring also raise risk. Other risk factors include type 2 diabetes (linked to about a threefold higher risk), being overweight or obese, smoking, and hereditary hemochromatosis, which is estimated to lead to HCC in 8-10% of patients. Regular exposure to aflatoxins, a mold toxin found in poorly stored grains, nuts, and spices, and to chemicals such as solvents and pesticides can also contribute. Some risks can be lowered. Hepatitis B can be prevented with vaccination, hepatitis C can often be treated successfully, and limiting alcohol, stopping smoking, and managing weight and diabetes all help protect the liver.
In people with cirrhosis or chronic hepatitis B, imaging alone can confirm HCC. Doctors use a contrast-enhanced, multiphase CT or MRI scan and look for a typical pattern: the tumor lights up in the early (arterial) phase, then the contrast fades out (washout) in later phases. Radiologists grade these findings with a system called LI-RADS. A blood test for alpha-fetoprotein (AFP) cannot diagnose HCC on its own, because it is not accurate enough. In other cases, such as when imaging is unclear or the person does not have cirrhosis, a liver biopsy is generally needed to confirm the diagnosis.
Yes, especially when it is caught early. HCC that is still confined to the liver can often be treated successfully with surgery or liver transplant, and both can be curative for selected patients. Surgical resection is the treatment of choice for localized HCC when there is no cirrhosis. For people with cirrhosis who meet transplant criteria, a transplant treats both the cancer and the damaged liver. When surgery is not an option, treatments delivered directly to the tumor, such as ablation or TACE, can help control the cancer. Outlook depends heavily on how far the cancer has spread: about 31% of people with localized HCC are alive at least 5 years after diagnosis, compared with about 11% for regional and 3% for distant disease. Cancer can return after treatment, so follow-up imaging continues. A multidisciplinary care team usually guides these decisions.
People with cirrhosis of any cause should be screened, as should certain people with chronic hepatitis B, depending on age and other criteria. The standard screening is a liver ultrasound every 6 months, often paired with an AFP blood test, even if you feel well. Screening continues after a successful hepatitis C cure if you have cirrhosis. An ultrasound every 6 months is also recommended for people with hereditary hemochromatosis who have cirrhosis, and suggested for those with advanced (bridging) fibrosis. Surveillance is not recommended for people with Child-Turcotte-Pugh C cirrhosis who are not eligible for a transplant, or for those with other serious conditions that limit life expectancy. Ask your hepatologist whether screening is right for you.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
